EUVIMEDEUVIMED entdecken
Crossref

The impact of letermovir prophylaxis in matched sibling donor haematopoietic stem cell transplantation: Selecting the appropriate population for optimal prophylactic therapy

Sisi Zhen, Li Liu, Futong Liu, Yuyan Shen iD, Tingting Zhang iD, Yuping Fan, Yuqing Cui, Ling Pan, Chen Liang, Yigeng Cao iD, Wenbin Cao, Jialin Wei und 10 weitere

British Journal of Haematology · 2025-09 · 207 (3) · 965-976

DOI: 10.1111/bjh.70016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 21.07.2025. Verfasst von Sisi Zhen und 21 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Hematopoie…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Antiviral Agents, Acetates. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Beijing Xisike Clinical Oncology Research Foundation, National Key R&D Program of China, Noncommunicable Chronic Diseases-National Science and Technology Major Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Letermovir (LTV) effectively prevents cytomegalovirus (CMV) reactivation in CMV‐seropositive patients. To evaluate the impact of LTV in matched sibling haematopoietic stem cell transplantation (HSCT) recipients, we retrospectively compared 72 matched sibling transplantation recipients receiving LTV with 134 controls. LTV significantly reduced 200‐day CMV viraemia incidence (5.6% vs. 33.3%, p < 0.001). Multivariable analysis identified anti‐thymocyte globulin (ATG) use ( p = 0.005) and grade III–IV acute graft‐versus‐host disease (aGVHD; p < 0.001) as independent risk factors for CMV viraemia, while CMV serostatus did not significantly affect CMV viraemia ( p = 0.448). Stratification based on risk factors (ATG, grade III–IV aGVHD) showed that LTV had a more significant effect on high‐risk patients compared to low‐risk patients. Also, LTV prophylaxis was associated with increased Epstein–Barr virus (EBV) viraemia (13.9% vs. 1.4%, p = 0.025) and higher CD20 monoclonal antibody utilization (11.1% vs. 1.4%, p = 0.046). Long‐term survival remained similar between both groups. Results were validated in a second cohort from our centre. In conclusion, LTV prophylaxis significantly reduced CMV viraemia, especially in high‐risk patients (ATG/grade III–IV aGVHD). However, the LTV group showed an elevated risk of EBV‐related complications. Risk stratification—rather than CMV serostatus alone—should guide CMV prevention strategies in matched sibling HSCT. Larger clinical studies are needed for validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationCytomegalovirus InfectionsAntiviral AgentsAcetatesQuinazolinesHumansMaleFemaleMiddle AgedAdultSiblingsRetrospective StudiesViremiaAdolescentYoung AdultGraft vs Host DiseaseRisk FactorsCytomegalovirusAged

Stichwörter der Autor:innen

CMV reactivationEBV reactivationhaematopoietic stem cell transplantationletermovirmatched sibling donor

Substanzen

letermovirAntiviral AgentsAcetatesQuinazolines

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Hematopoietic Stem Cell Transplantation Center, Institute of Hematology & Blood…
  • Tianjin Institutes of Health Science, Tianjin, P. R. China.
  • Haihe Laboratory of Cell Ecosystem, Tianjin Medical University, Tianjin, P. R. China.

ORCID-Profile: Yuyan Shen, Tingting Zhang, Yigeng Cao, Weihua Zhai, Rongli Zhang, Sizhou Feng

Förderung

  • Beijing Xisike Clinical Oncology Research Foundation
  • National Key R&D Program of China
  • Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • National Natural Sciences Foundation of China
  • the Fundamental Research Funds for the Central Universities, Peking Union Medical College
  • Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
  • National Key Research and Development Program of China

Zitieren

APA

Zhen, S., Liu, L., Liu, F., Shen, Y., Zhang, T., Fan, Y., Cui, Y., Pan, L., Liang, C., Cao, Y., Cao, W., Wei, J., Zhai, W., Chen, X., Ma, Q., Zhang, R., Yang, D., He, Y., Pang, A., …, & Feng, S. (2025). The impact of letermovir prophylaxis in matched sibling donor haematopoietic stem cell transplantation: Selecting the appropriate population for optimal prophylactic therapy. British Journal of Haematology, 207(3), 965-976. https://doi.org/10.1111/bjh.70016

Vancouver

Zhen S, Liu L, Liu F, Shen Y, Zhang T, Fan Y, et al. The impact of letermovir prophylaxis in matched sibling donor haematopoietic stem cell transplantation: Selecting the appropriate population for optimal prophylactic therapy. British Journal of Haematology. 2025;207(3):965-976. doi:10.1111/bjh.70016

BibTeX
@article{Zhen2025,
  author = {Zhen, Sisi and Liu, Li and Liu, Futong and Shen, Yuyan and Zhang, Tingting and Fan, Yuping and Cui, Yuqing and Pan, Ling and Liang, Chen and Cao, Yigeng and Cao, Wenbin and Wei, Jialin and Zhai, Weihua and Chen, Xin and Ma, Qiaoling and Zhang, Rongli and Yang, Donglin and He, Yi and Pang, Aiming and Han, Mingzhe and Jiang, Erlie and Feng, Sizhou},
  title = {The impact of letermovir prophylaxis in matched sibling donor haematopoietic stem cell transplantation: Selecting the appropriate population for optimal prophylactic therapy},
  journal = {British Journal of Haematology},
  year = {2025},
  volume = {207},
  number = {3},
  pages = {965--976},
  doi = {10.1111/bjh.70016}
}
Kostenlos starten →